SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED CALCIUM ION CHANNEL CAV2.3 ANTAGONISTS
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: Formula (I) wherein Ring A, R1, R2, R3, R4 and a are as defined herein. The compounds are antagonists5 of the resistant (R-type) voltage-gated calcium ion channel Cav 2.3. Also disclosed are pharmaceutical comp...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | PEVARELLO, Paolo CATALANI, Maria Pia STEINHAGEN, Henning |
| description | Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: Formula (I) wherein Ring A, R1, R2, R3, R4 and a are as defined herein. The compounds are antagonists5 of the resistant (R-type) voltage-gated calcium ion channel Cav 2.3. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases modulated Cav 2.3, including epilepsy, neurodegenerative conditions such as Parkinson's disease, focal, drug-resistant forms of epilepsy, and other neurological disorders such as developmental and epileptic encephalopathies and Fragile X syndrome.10
L'invention concerne des composés de formule (I), et leurs sels pharmaceutiquement acceptables : Formule (I) dans laquelle le cycle A, R1, R2, R3, R4 et a sont tels que définis dans la description. Les composés sont des antagonistes du canal ionique calcique voltage-dépendant Cav 2.3 résistant (de type R). L'invention concerne également des compositions pharmaceutiques comprenant les composés ; et les composés destinés à être utilisés dans le traitement de maladies modulées par Cav 2.3, y compris l'épilepsie, des états neurodégénératifs tels que la maladie de Parkinson, des formes focales, pharmacorésistantes de l'épilepsie, et d'autres troubles neurologiques tels que les encéphalopathies développementales et épileptiques et le syndrome X fragile. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2024246523A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2024246523A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2024246523A13</originalsourceid><addsrcrecordid>eNqNyrEKwjAQgOEsDqK-w4FzRZPqfiRpG0juhCR1LEXiJFqo748dfACnH36-tQgx-4YJgzMWNIcrZzIRMELPPmFrqxaTNaDRa5cDOCbQHRJZv7xeHhQgLY7JxRS3YvUYn3PZ_boR-8Ym3VVleg9lnsZ7eZXPcGN5lLWsL2ep8KT-U1-G2y7c</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED CALCIUM ION CHANNEL CAV2.3 ANTAGONISTS</title><source>esp@cenet</source><creator>PEVARELLO, Paolo ; CATALANI, Maria Pia ; STEINHAGEN, Henning</creator><creatorcontrib>PEVARELLO, Paolo ; CATALANI, Maria Pia ; STEINHAGEN, Henning</creatorcontrib><description>Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: Formula (I) wherein Ring A, R1, R2, R3, R4 and a are as defined herein. The compounds are antagonists5 of the resistant (R-type) voltage-gated calcium ion channel Cav 2.3. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases modulated Cav 2.3, including epilepsy, neurodegenerative conditions such as Parkinson's disease, focal, drug-resistant forms of epilepsy, and other neurological disorders such as developmental and epileptic encephalopathies and Fragile X syndrome.10
L'invention concerne des composés de formule (I), et leurs sels pharmaceutiquement acceptables : Formule (I) dans laquelle le cycle A, R1, R2, R3, R4 et a sont tels que définis dans la description. Les composés sont des antagonistes du canal ionique calcique voltage-dépendant Cav 2.3 résistant (de type R). L'invention concerne également des compositions pharmaceutiques comprenant les composés ; et les composés destinés à être utilisés dans le traitement de maladies modulées par Cav 2.3, y compris l'épilepsie, des états neurodégénératifs tels que la maladie de Parkinson, des formes focales, pharmacorésistantes de l'épilepsie, et d'autres troubles neurologiques tels que les encéphalopathies développementales et épileptiques et le syndrome X fragile.</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241205&DB=EPODOC&CC=WO&NR=2024246523A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241205&DB=EPODOC&CC=WO&NR=2024246523A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>PEVARELLO, Paolo</creatorcontrib><creatorcontrib>CATALANI, Maria Pia</creatorcontrib><creatorcontrib>STEINHAGEN, Henning</creatorcontrib><title>SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED CALCIUM ION CHANNEL CAV2.3 ANTAGONISTS</title><description>Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: Formula (I) wherein Ring A, R1, R2, R3, R4 and a are as defined herein. The compounds are antagonists5 of the resistant (R-type) voltage-gated calcium ion channel Cav 2.3. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases modulated Cav 2.3, including epilepsy, neurodegenerative conditions such as Parkinson's disease, focal, drug-resistant forms of epilepsy, and other neurological disorders such as developmental and epileptic encephalopathies and Fragile X syndrome.10
L'invention concerne des composés de formule (I), et leurs sels pharmaceutiquement acceptables : Formule (I) dans laquelle le cycle A, R1, R2, R3, R4 et a sont tels que définis dans la description. Les composés sont des antagonistes du canal ionique calcique voltage-dépendant Cav 2.3 résistant (de type R). L'invention concerne également des compositions pharmaceutiques comprenant les composés ; et les composés destinés à être utilisés dans le traitement de maladies modulées par Cav 2.3, y compris l'épilepsie, des états neurodégénératifs tels que la maladie de Parkinson, des formes focales, pharmacorésistantes de l'épilepsie, et d'autres troubles neurologiques tels que les encéphalopathies développementales et épileptiques et le syndrome X fragile.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyrEKwjAQgOEsDqK-w4FzRZPqfiRpG0juhCR1LEXiJFqo748dfACnH36-tQgx-4YJgzMWNIcrZzIRMELPPmFrqxaTNaDRa5cDOCbQHRJZv7xeHhQgLY7JxRS3YvUYn3PZ_boR-8Ym3VVleg9lnsZ7eZXPcGN5lLWsL2ep8KT-U1-G2y7c</recordid><startdate>20241205</startdate><enddate>20241205</enddate><creator>PEVARELLO, Paolo</creator><creator>CATALANI, Maria Pia</creator><creator>STEINHAGEN, Henning</creator><scope>EVB</scope></search><sort><creationdate>20241205</creationdate><title>SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED CALCIUM ION CHANNEL CAV2.3 ANTAGONISTS</title><author>PEVARELLO, Paolo ; CATALANI, Maria Pia ; STEINHAGEN, Henning</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2024246523A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>PEVARELLO, Paolo</creatorcontrib><creatorcontrib>CATALANI, Maria Pia</creatorcontrib><creatorcontrib>STEINHAGEN, Henning</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>PEVARELLO, Paolo</au><au>CATALANI, Maria Pia</au><au>STEINHAGEN, Henning</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED CALCIUM ION CHANNEL CAV2.3 ANTAGONISTS</title><date>2024-12-05</date><risdate>2024</risdate><abstract>Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: Formula (I) wherein Ring A, R1, R2, R3, R4 and a are as defined herein. The compounds are antagonists5 of the resistant (R-type) voltage-gated calcium ion channel Cav 2.3. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases modulated Cav 2.3, including epilepsy, neurodegenerative conditions such as Parkinson's disease, focal, drug-resistant forms of epilepsy, and other neurological disorders such as developmental and epileptic encephalopathies and Fragile X syndrome.10
L'invention concerne des composés de formule (I), et leurs sels pharmaceutiquement acceptables : Formule (I) dans laquelle le cycle A, R1, R2, R3, R4 et a sont tels que définis dans la description. Les composés sont des antagonistes du canal ionique calcique voltage-dépendant Cav 2.3 résistant (de type R). L'invention concerne également des compositions pharmaceutiques comprenant les composés ; et les composés destinés à être utilisés dans le traitement de maladies modulées par Cav 2.3, y compris l'épilepsie, des états neurodégénératifs tels que la maladie de Parkinson, des formes focales, pharmacorésistantes de l'épilepsie, et d'autres troubles neurologiques tels que les encéphalopathies développementales et épileptiques et le syndrome X fragile.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2024246523A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED CALCIUM ION CHANNEL CAV2.3 ANTAGONISTS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T23%3A40%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=PEVARELLO,%20Paolo&rft.date=2024-12-05&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2024246523A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |